(Endometrial Cancer) Chemoradiotherapy vs. Radiotherapy Alone: PORTEC-3 Phase 3 Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- September 23, 2019
- 2 min read
On July 10, 2019, Stephanie M. de Boer published results in The Lancet Oncology from the PORTEC-3 Phase 3 clinical trial comparing the efficacy and safety of radiotherapy alone versus combined chemoradiotherapy in high-risk endometrial cancer patients.
Trial Design:
The PORTEC-3 trial enrolled high-risk endometrial cancer patients (N=660) in a 1:1 randomized Phase 3 design. Primary endpoints were 5-year overall survival (OS) and 5-year progression-free survival (PFS).
- Radiotherapy group (N=330): 48.6 Gy radiation
- Chemoradiotherapy group (N=330): Cisplatin 50 mg/m² + radiotherapy (48.6 Gy), followed by carboplatin + paclitaxel 175 mg/m²
Results at median follow-up of 72.6 months:
Primary endpoints:
- 5-year OS: Radiotherapy 76.1% vs. chemoradiotherapy 81.4%
- 30% reduction in disease progression or death risk (HR: 0.70)
- 5-year PFS: Radiotherapy 69.1% vs. chemoradiotherapy 76.5%
- 30% reduction in disease progression or death risk (HR: 0.70)
Secondary endpoint:
- 5-year distant metastasis rate: Radiotherapy 29.1% vs. chemoradiotherapy 21.4%
- 26% reduction in distant metastasis risk (HR: 0.74)
Safety:
Grade 3+ adverse events: Radiotherapy 5% vs. chemoradiotherapy 8% — no significant difference between groups. Grade 3+ hypertension: 2% in both groups. At 5 years from treatment initiation, Grade 2+ adverse events: Radiotherapy 23% vs. chemoradiotherapy 38%.
Conclusion: Based on the PORTEC-3 trial results, Stephanie M. de Boer concluded that combined chemoradiotherapy significantly improved 5-year OS and 5-year PFS compared to radiotherapy alone in high-risk endometrial cancer patients.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Jul 22. doi:10.1016/S1470-2045(19)30395-X
Endometrial Cancer
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4